Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care - 19/01/22
Proposition de cadre général pour l’administration des immunothérapies anticancéreuses en hospitalisation à domicile
, Amélie Feyeux 2, Maurice Pérol 3, Nicolas Girard 4, Aurida El Bouanani 5, Antoine Vignon 5, Aldo Renault 5Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Immunotherapy has transformed the treatment paradigm of several cancers. Hospital-at-home (HAH) care is an innovative healthcare model in which treatments are delivered at home under the supervision of a hospital, which likely applies to cancer immunotherapy. For this home-care option, official treatment guidelines are still lacking. We therefore sought to create guidance and recommendations on how to administer immune response checkpoint inhibitor therapies and other monoclonal antibodies used in cancer treatment in the context of HAH setting.
Methods |
A multidisciplinary group of healthcare professionals with expertise in managing cancer patients and prescribing immunotherapy in HAH settings was set up.
Results |
Based on the survey results and working group discussions, six major components were identified: (1) existing HAH organization in France; (2) underlying framework; (3) flowchart; (4) patient pathway before, the day of, and after immunotherapy; (5) healthcare personnel training; (6) patient therapeutic education. The detailed specifications for each component are provided herein, along with an illustrative flowchart. The prerequisites for home administration of cancer immunotherapies are summarized in Table 1.
Discussion |
This paper seeks to facilitate the implementation of cancer immunotherapy within HAH settings for the healthcare professionals concerned.
Le texte complet de cet article est disponible en PDF.Keywords : Home-based immunotherapy, Hospital-at-home, Cancer survivors, Advanced cancer, Patient satisfaction, Checkpoint inhibitors
Plan
Vol 109 - N° 1
P. 98-105 - janvier 2022 Retour au numéro
Article précédent
- Immune checkpoint inhibitors and hospitalization at home in France
- Elisa Gobbini, Anne-Claire Toffart, Laure Boisserie Lacroix, Julian Pinsolle, Laure Schoutteten, Isabelle Federspiel, Thomas Pierret, Maurice Pérol, Amélie Feyeux
- Professeur Axel Kahn : quand la science et la passion animent un Grand Homme
- Daniel Nizri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?